Association between subclonal and clonal TP53 deletion and survival in newly diagnosed myeloma. Kaplan-Meier survival curves showing progression-free survival (A) and OS (B) of 3 approximately equal-sized TP53-deleted clonal subgroups vs no TP53 deletion in 1777 patients in the Myeloma XI trial. OS evaluation of the above subgroups in landmarked analysis from the time of high-dose melphalan and autologous stem cell transplant (C) and from the time of maintenance randomization (D).